Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For all participants:

• People aged 40 to 80 years.
• People who are covered by social security insurance or are a named beneficiary of such coverage.
• People who have signed an informed consent form, either personally or through a legal representative.

For the Alzheimer's disease group (AD-Y):

• People who have had cerebrospinal fluid (a fluid around the brain and spine) tested, with results showing specific protein levels that indicate Alzheimer's disease (confirm with trial site for exact values).
• People who have had a positive PET brain scan showing amyloid deposits (a protein linked to Alzheimer's disease).
• People who developed memory problems before age 65, with a gradual onset, and whose memory testing shows a specific pattern of difficulty linked to a part of the brain called the hippocampus.

For the Posterior Cortical Atrophy group (PCA):

• People whose brain test results show signs of Alzheimer's disease in the brain, as described above.
• People who have significant difficulties with visual processing — such as recognising objects, words, symbols, or faces — without major memory or problem-solving difficulties.
• People who show a specific pattern of visual-spatial difficulties, which may include problems with spatial awareness, coordinating movements, or attention to one side of the visual field.

For the healthy control group:

• People with normal results on neurological and cognitive assessments.
• People whose age is similar to that of the patient participants (matching will be done by the trial site).

Who may not be able to join:

General criteria applying to all participants:

• People with a history of a specific dangerous heart rhythm problem called torsade de pointes, or those considered at risk of developing it.
• People currently taking medications known to affect heart rhythm in a way that increases that risk (a reference list is available at www.crediblemeds.org).
• People with kidney function below a certain level, liver problems, or other significant abnormal blood test results of a certain severity, as these may prevent participation in the imaging part of the trial.
• People who are unable to give informed consent themselves and do not have a legal representative able to do so on their behalf.
• People who are legally detained or who do not have social security coverage.
• People who are currently taking part in another clinical trial involving a treatment, or who are within an exclusion period from a previous trial.
• People who cannot have an MRI scan, such as those with a pacemaker, heart defibrillator, certain implanted devices, certain surgical metal clips in the brain or neck, or certain orthopaedic implants.
• People with a known allergy to the radioactive substance used in the PET scan or any of its ingredients.
• People who experience claustrophobia (fear of enclosed spaces).
• People who are pregnant (women of childbearing age will be asked to take a urine pregnancy test on the day of the scan visit).
• People with symptoms or test results suggesting serious problems with the kidneys, liver, heart, lungs, or other organs that could affect test results or their health during the trial.
• People under a formal legal protection order (confirm with trial site).

For Alzheimer's disease and PCA patient groups only:

• People whose cognitive difficulties appeared suddenly rather than gradually.
• People who have significant walking difficulties, seizures, or major changes in behaviour.
• People who show certain signs on neurological examination, such as movement disorders, hallucinations, or fluctuating cognitive ability.
• People with a psychiatric condition, stroke-related condition, metabolic disorder, or inflammatory brain condition.

For healthy control participants only:

• People with an abnormal neurological examination.
• People with a history of neurological disease (such as stroke or a neurodegenerative condition) or a psychiatric illness (such as severe depression, psychosis, or bipolar disorder that still requires medication).
• People with a serious physical condition that could affect cognitive functioning.

Important: Always verify eligibility with the trial site directly before applying.